Regarding the clinical utility of selective KOR antagonists for mood disorders, though both the negative affect/dysphoria model and the novelty processing model predict that KOR antagonism could reduce depression and excessive drug use, the two frameworks diverge regarding implementation strategy. Here, OPRK1 is linked to depressive symptom measurement.